| Date | Title | Description |
| 09.04.2026 | AI Pioneers Unite to Launch the Shared AI License Foundation to Advance Foundation Model Innovation | A new coalition of technology and innovation leaders has launched the Shared AI License Foundation (SAIL), the first organization dedicated to safeguarding AI innovation through a collaborative patent network. This initiative, led by foundi... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 01.04.2026 | Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma | SHANGHAI, April 1, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inh... |
| 31.03.2026 | Zürich-based Starmind acquired by US AI platform company Capacity |
For years, companies have invested in documenting knowledge across wikis, intranets, and knowledge bases. With the rise of generative AI, this documented knowledge has become more accessible than ever. Yet a fundamental problem remains: a ... |
| 30.03.2026 | Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year | TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximat... |
| 30.03.2026 | Роскошный отель на Луне и роботы-пастухи: что показали самые безумные стартапы на YC Demo Day | Зимняя сессия стартап-акселератора Y Combinator 2026 года показала резкий рост стоимости таких предприятий. Базовая оценка компаний на посевной стадии удвоилась и достигла $30 млн. Отдельные проекты закрывали сделки с оценкой в $100 млн. Но... |
| 27.03.2026 | AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed | Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.
The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former s... |
| 21.03.2026 | Candex Secures $40M+ HSBC Investment for Global Tail Spend Dominance | Candex closed over $40M in Series C extension funding. Strategic investment came from HSBC. Total funding now surpasses $120M. This capital targets massive global infrastructure growth. Expansion into Asia is a key focus. Platform capabilit... |
| 18.03.2026 | Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy | TAIPEI and SAN DIEGO, March 18, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announce... |
| 18.03.2026 | Mankind Pharma acquires Roche’s Rivotril brand for India, bolsters CNS presence | - |
| 17.03.2026 | Roche Launches NVIDIA AI Factory to Accelerate the Development of New Therapeutics and Diagnostics Solutions | Roche announced that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI. Featuring 2,176 high-performance GPUs on premises ac... |
| 17.03.2026 | Candex: $40+ Million Series C Extension Raised To Scale Tail-Spend Management Platform | Candex, a technology-based vendor management platform focused on simplifying enterprise tail spend, has extended its Series C funding round to more than $40 million with a strategic investment from HSBC, bringing total funding to over $120 ... |
| 17.03.2026 | Candex Extends Series C to $40M+ with Strategic Investment from HSBC | Candex, a NYC-based vendor-management and tail-spend-solutions provider for global enterprises, extended its Series C funding to over $40M with a strategic investment from HSBC.
The raise brought the total funding to over $120M and added HS... |
| 17.03.2026 | Roche ramps up AI computing capacity with Nvidia chip expansion | BERLIN, March 16 : Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to support drug and diagnostics development.
Roche said the additional hardware would s... |
| 16.03.2026 | Nvidia launches enterprise AI agent platform with Adobe, Salesforce, SAP among 17 adopters at GTC 2026 | Jensen Huang walked onto the GTC stage Monday wearing his trademark leather jacket and carrying, as it turned out, the blueprints for a new kind of monopoly.
The Nvidia CEO unveiled the Agent Toolkit, an open-source platform for building au... |
| 14.03.2026 | ORO Labs Secures $100M to Revolutionize Enterprise AI Procurement | ORO Labs, an AI-driven procurement orchestration leader, secured $100 million in Series C funding. This capital injection follows a year of 300% revenue growth. The platform modernizes enterprise procurement. It streamlines complex global s... |
| 13.03.2026 | These stocks will benefit from AI and an aging population, Jefferies says. They also pay dividends | - |
| 13.03.2026 | Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics | Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datas... |
| 12.03.2026 | Dividend stocks are going gangbusters in 2026. Here’s what investors are doing with the extra cash | - |
| 12.03.2026 | ORO Labs raises $100M to expand procurement orchestration platform
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Procurement orchestration platform company ORO Labs Inc. announced today that it has raised $100 million in new funding to accelerate its expansion, further develop its product and scale up customer success and deployment worldwide.
Founded... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 06.03.2026 | Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’ | Shares of Danish drugmaker Zealand Pharma fell more than 35% after trial patients lost less weight than expected with its experimental medicine.
CEO Adam Steensberg told CNBC that, in the real world, Zealand’s drug offers massive potential ... |
| 03.03.2026 | Global Forum Head Ousted Over Epstein Links | Borge Brende, World Economic Forum CEO, resigned under pressure. His departure followed intense scrutiny over past connections with convicted sex offender Jeffrey Epstein. An independent review found no new revelations beyond previously dis... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 02.03.2026 | Emcure in pact with Roche to distribute select nephrology and transplant medicines | - |
| 27.02.2026 | BreezeBio: $60 Million Series B Raised To Advance Precision Genetic Medicines Pipeline | BreezeBio, formerly known as GenEdit, has closed $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and expand its NanoGalaxy delivery platform.
The South San Francisco-based biotechnology... |
| 26.02.2026 | CEO of World Economic Forum quits after Epstein ties come to light | ZURICH: The president and CEO of the World Economic Forum, Borge Brende, said on Thursday (Feb 26) he was stepping down, a few weeks after the forum launched an independent investigation into his relationship with late US sex offender Jeffr... |
| 26.02.2026 | BreezeBio Closes Series B Funding | BreezeBio, (fka as GenEdit), a San Francisco, CA-based biotechnology company developing genetic medicines, raised an undisclosed amount in Series B funding.
The round was led by Yuanta Investment and DSC Investment, with participation from ... |
| 25.02.2026 | These 4 charts show the scale of Novo Nordisk’s woes | Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk.
The Danish company is less diversified than current and future competitors, and increasingly exposed to the U.S. market, where drug prices are com... |
| 23.02.2026 | Katalysen Ventures Forges Ahead: Strategic Moves Define Q4 2025 and Future Growth | Katalysen Ventures closed Q4 2025 with strategic vigor. Core investments surged, now comprising most of its portfolio value. Multiple directed share issues strengthened capital and broadened its investor base. New B2B tech additions like S4... |
| 23.02.2026 | Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and... |
| 17.02.2026 | Katalysen Ventures publishes report for the Fourth Quarter 2025 | Katalysen Ventures publishes report for the Fourth Quarter 2025
Tue, Feb 17, 2026 08:13 CET Report this content
Katalysen Ventures AB (publ) hereby publishes the report for the Fourth Quarter 2025. The full report is available immediately a... |
| 13.02.2026 | Prices, pipelines and patent cliffs: Inside pharma’s big reset | Pharma earnings weren’t the main focus for drugmakers this quarter.
“2025 was about understanding kind of the rules of the future of the game,” McKinsey Senior Partner Greg Graves told CNBC.
In addition to political dealings, companies are ... |
| 12.02.2026 | Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF | SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a ... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 04.02.2026 | Genentech Awards Grant to Support Science Center's Translation Project | One-year grant will support activities designed to close the gap between breakthrough innovation and patient impact
PHILADELPHIA, Feb. 4, 2026 /PRNewswire-PRWeb/ -- The Science Center, a premier catalyst of entrepreneurial activity, healthc... |
| 04.02.2026 | From blood tests to orbital labs: Europe’s next generation of cancer tech | Today, February 4, is World Cancer Day. Cancer kills around 10 million people each year — more than HIV/AIDS, malaria, and tuberculosis combined.
Fortunately, European startups are accelerating innovation across the cancer care pipeline, fr... |
| 02.02.2026 | 3 Ways Health Brands Can Design Digital Experiences That Users Won’t Abandon | According to new research, nearly half of users ultimately abandon the digital health or wellness technologies they adopt. This startling finding reveals a major challenge amid the industry’s rapid growth.
Health and wellness technologies a... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 02.02.2026 | SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech | - SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech
- SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling u... |
| 31.01.2026 | Markets Eye Fed, Tech Titans Amid Global Shifts | The Federal Reserve held interest rates steady, defying calls for immediate cuts. Major tech earnings reports from Meta, Microsoft, and Tesla delivered mixed investor reactions. The S&P 500 briefly crossed 7,000. Geopolitical tensions i... |
| 30.01.2026 | PharmNovo enhances its Board ahead of Phase II development | PharmNovo enhances its Board ahead of Phase II development
Fri, Jan 30, 2026 08:04 CET Report this content
PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli... |
| 30.01.2026 | ORamaVR secures $4.5M to scale medical XR simulations |
Headquartered in Geneva with offices in Crete, Greece, ORamaVR is building Computational Medical Extended Reality (CMXR), a special category of virtual reality software where AI, medical knowledge, robotic digital twins, and real-time anal... |
| 29.01.2026 | Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite | Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock.
As pharma companies face a “patent cliff” where existing drugs lose exclusivity, the companies talked up what they have in ... |
| 29.01.2026 | European markets open higher as earnings ‘super Thursday’ unfolds, SAP tumbles | LONDON — European stocks advanced on Thursday, as traders focused on a raft of earnings reports from some of Europe’s biggest companies.
The pan-European Stoxx 600 was up 0.5% shortly after 12:30 p.m. in London (7:30 a.m. ET) following the ... |
| 29.01.2026 | CNBC Daily Open: Investors expected the Fed to hold rates — it was Powell’s comments that drew interest | Fed keeps interest rates unchanged, as expected.
Nvidia’s AI boom has ASML to thank.
SK Hynix beat rival Samsung Electronics in operating profit for the first time.
The S&P 500 briefly surpassed 7,000 but closed flat.
Analysts say U.S. ... |
| 29.01.2026 | Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" | HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-dep... |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 22.01.2026 | Greenland Gambit: US Tariffs Ignite EU's Trade Bazooka | The US-EU trade relationship faces unprecedented strain. President Trump demands Greenland's sale, threatening harsh tariffs on key European economies. Europe weighs fierce retaliation. The EU's "Anti-Coercion Instrument," dubbed ... |
| 20.01.2026 | Another alliance of health care and AI signals why pharma stocks should be back in favor | - |
| 20.01.2026 | CNBC Daily Open: A trade ‘bazooka’ against Trump’s Greenland tariffs is in the cards for the EU | Trump said he would slap 200% tariffs on French wines and champagne.
China’s regulators tightened margin financing rules after trading activity surged to highs.
Private credit still drawing investors even as warnings mount over looser loan ... |
| 20.01.2026 | CNBC Daily Open: The EU has a trade ‘bazooka’ to deal with Trump’s Greenland tariffs — and is mulling over it | Europe weighs using trade “bazooka” against the U.S.
Powell to attend Supreme Court arguments regarding Fed Governor Lisa Cook.
Putin invited to join Trump’s “Board of Peace,” Kremlin says.
Stock futures indicated the Dow is set to open wit... |
| 19.01.2026 | Inequality and unease are rising as elite Davos event opens with pro-business Trump set to attend | Getting your Trinity Audio player ready...
By JAMEY KEATEN
DAVOS, Switzerland (AP) — Corporate chiefs and government leaders including U.S. President Donald Trump swarm into Davos, Switzerland, this week, joining an elite annual meeting tha... |
| 19.01.2026 | Here are the European exporters most exposed if Trump’s Greenland tariffs kick in | Trump has pledged to impose 10% tariffs on eight European countries from Feb. 1, ramping up his push to make Greenland a part of the United States.
The levy will rise to 25% from June 1, Trump said.
CNBC takes a look at some of the most exp... |
| 19.01.2026 | Chinese Innovative Drugs' Global Rise Is Hot Topic at JP Morgan Healthcare Conference | (Yicai) Jan. 19 -- Chinese innovative drugs were an unavoidable topic among participants at the 44th annual JP Morgan Healthcare Conference due to their growing importance in the global pharmaceutical industry, with discussion focusing on i... |
| 18.01.2026 | Davos Summit Confronts Geopolitical Storms as Trump Pursues Greenland | President Trump leads a record U.S. delegation to Davos, sparking intense global scrutiny. The World Economic Forum convenes amidst escalating geopolitical tensions. Trump's aggressive pursuit of Greenland ignites fears of a significant U.S... |
| 18.01.2026 | Trump's Dual Strategy: Tariffs Threaten Europe, Davos Beckons Global Elite | President Trump pushes global boundaries. He threatens escalating tariffs on key European allies. The ultimatum targets eight nations over Greenland's refusal to sell. Allies condemn the aggressive stance as unacceptable. Simultaneously, Tr... |
| 18.01.2026 | Trump's Global Stage: Davos Diplomacy Meets Greenland Tariff Showdown | President Trump's aggressive foreign policy sparks global tension. He demands Greenland, threatening tariffs on European allies. This confrontation coincides with his attendance at the World Economic Forum in Davos, where leaders discuss gl... |
| 18.01.2026 | Swiss companies looking to tap into India opportunity, ramp up investments | - |
| 14.01.2026 | TECregen Secures CHF 10 Million, Appoints Chairman to Propel Immune Rejuvenation | Swiss biotech TECregen secured CHF 10 million in seed funding. This investment propels its pioneering thymus-rejuvenating biologics. The goal: restore robust immune function, counter age-related decline, and tackle serious diseases. Boehrin... |
| 13.01.2026 | Trump set to lead largest-ever US delegation to World Economic Forum in Davos next week | Getting your Trinity Audio player ready...
GENEVA (AP) — U.S. President Donald Trump will return to the World Economic Forum’s annual meeting of business, political and cultural elites in Davos, Switzerland, next week, leading a record-larg... |
| 09.01.2026 | KAHR Bio: $22 Million Raised And Phase 2 Topline Data For DSP107 Combo In MSS Colorectal Cancer | KAHR Bio announced it posted “strong” topline results from a Phase 2a dose-expansion cohort evaluating its investigational immunotherapy DSP107 in combination with Roche’s atezolizumab (Tecentriq) in late-line metastatic microsatellite stab... |
| 09.01.2026 | MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche | SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the developm... |
| 09.01.2026 | A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year | Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine.
Now, analysts say the French biotech could be bought by a ... |
| 08.01.2026 | Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD | SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidat... |
| 08.01.2026 | TECregen Raises CHF 10 Million Seed Round, Names Dr. Bo Rode Hansen Chairman | Basel, Switzerland-based TECregen has raised CHF 10 million (approximately €10.7 million / $12.6 million) in seed financing to advance a new class of thymus-rejuvenating biologics aimed at restoring immune function by rejuvenating thymic ep... |
| 06.01.2026 | Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD | SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidat... |
| 01.01.2026 | Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market | 2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China.
It follows a difficult year for Novo, marked by volatility a... |
| 25.12.2025 | Oral GLP-1 Revolution: Novo Nordisk Secures First FDA Approval for Obesity Pill | The FDA approved Novo Nordisk's pivotal GLP-1 pill for obesity. This oral treatment, launching early 2026 at $149/month, revolutionizes weight loss access and patient choice. It secures Novo Nordisk a critical first-mover advantage over Eli... |
| 23.12.2025 | Novo Nordisk stock surges on hopes Wegovy pill approval will deliver ‘redemption’ for investors | The FDA on Monday approved the first-ever GLP-1 pill from Novo Nordisk.
The approval gives the Danish pharma giant a head start against U.S. rival Eli Lilly.
“Novo actually might have an edge, and it will entirely depend on how they execute... |
| 21.12.2025 | Трамп договорился с фармакомпаниями о снижении цен на лекарства для хронических болезней | - |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | This is how exposed European Big Pharma is to the U.S. | The U.S. is the biggest single market for most pharma and biotech firms.
Among the 10 largest biopharmaceutical companies in the Stoxx 600 health index, five get a majority of their total sales from the U.S.
AstraZeneca gets 42% of sales fr... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 18.12.2025 | Bringing rapid, lab-grade diagnostics to the pond side | - |
| 17.12.2025 | DayOne Digital Health programs deliver impressive results |
Over 300 start-up founders, pharmaceutical industry leaders, investors and regional ecosystem stakeholders came together last week to take part in the two-day DayOne Innovation Showcase event at Roche Building 1. The focus on both days was... |
| 15.12.2025 | Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia | SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that he... |
| 12.12.2025 | Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity | After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly s... |
| 12.12.2025 | Болезням прописали инструкцию | - |
| 11.12.2025 | Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly | Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its “Metabolic Frontier 2030” strategy.
The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment... |
| 10.12.2025 | Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody | SAN FRANCISCO and SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 07.12.2025 | Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List | SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 03.12.2025 | China Launches First National Medicine Price Registration System | (Yicai) Dec. 3 -- China's first national drug price registration system independent from existing provincial drug procurement platforms was officially put into operation, providing pharmaceutical companies with an authoritative and transpar... |
| 02.12.2025 | China’s flu season brings a new wave of single-dose antivirals | One morning in mid-November, Shanghai office worker A Liang woke up with a tight throat and a wave of fatigue. By noon, a low fever had set in, a feeling entirely different from the mild cold she had just recovered from days earlier. That w... |
| 18.11.2025 | European stocks close at one-month low as AI bubble fears mount | LONDON — European bourses ended Tuesday’s session sharply lower as global markets pulled back on renewed concerns over artificial intelligence-linked stocks.
The pan-European Stoxx 600 was provisionally 1.8% lower at the end of trade, after... |
| 14.11.2025 | U.S. and Switzerland reach trade deal to lower tariffs to 15% | “We’ve essentially reached a deal with Switzerland,” U.S. Trade Representative Jamieson Greer told CNBC’s “Squawk Box” on Friday morning.
Duties will be reduced to 15%, the Swiss government said in a post on X, adding that further details w... |
| 12.11.2025 | EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A | TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercializ... |
| 12.11.2025 | EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A | TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercializ... |
| 06.11.2025 | Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study | Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study.
The highest dose of the weekly injection, called eloralintide, helped patients with ... |
| 06.11.2025 | Prothena Reports Third Quarter 2025 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and ... |
| 30.10.2025 | Flatiron Launches 6 AI-Powered Hematology Datasets to Advance Blood Cancer RWE | What You Should Know:
–Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced the launch of six new hematology Panoramic datasets, representing another ... |
| 30.10.2025 | ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection | SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory s... |
| 28.10.2025 | iPNOTE Raises $1M in Seed Funding | iPNOTE, a San Francisco, CA–based legal tech platform that streamlines intellectual property (IP) management, raised $1M in seed funding.
The round was led by AltaIR Capital, with participation from Hi2 Venture Fund and several angel invest... |
| 27.10.2025 | Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 | The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group
DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP... |
| 27.10.2025 | Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics | Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases.
NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabo... |
| 24.10.2025 | Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore | The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older.
SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- ... |
| 23.10.2025 | This CEO’s radical experiment has 90,000 people working without bosses: ‘I don’t have to consult with anybody’ | You may have noticed that middle managers’ jobs are disappearing.
Major employers — ranging from Amazon and Meta to companies like Walmart, UPS, and Estée Lauder — have made headlines in the post-Covid era for cutting layers of middle manag... |
| 23.10.2025 | European markets higher after major earnings reports; Gucci-owner Kering soars over 10% | LONDON — European stocks had a positive start on Thursday as investors looked to earnings reports for clues on business activity and confidence in the region.
The pan-European Stoxx 600 had gained 0.3% by 12:15 p.m. in London (7:15 a.m. ET)... |
| 17.10.2025 | S4DX Launches First UK Pilot, Strengthening Position in Rapidly Evolving Blood Diagnostics Market | S4DX Launches First UK Pilot, Strengthening Position in Rapidly Evolving Blood Diagnostics Market
Fri, Oct 17, 2025 14:46 CET Report this content
Katalysen Ventures AB (publ) (“Katalysen”) is pleased to announce that its portfolio venture a... |
